Latanoprost and pigmentation

Japanese Journal of Ophthalmology

Volumn 48, Issue 6, 2004, Pages 602-612

  Grierson, Ian ^a   Jonsson, Monica ^b   Cracknell, Kathryn ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b Pfizer Global R and D   (Sweden)

Author keywords

Hypertrichosis; Iris pigmentation; Latanoprost; Melanocyte; Ocular hypertension; Open angle glaucoma

Indexed keywords

ANTIGLAUCOMA AGENT; LATANOPROST; PROSTAGLANDIN DERIVATIVE; THIAMAZOLE; TIMOLOL; TRAVOPROST;

CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; EYE COLOR; EYELASH; HUMAN; HYPERTRICHOSIS; IRIS; LONG TERM CARE; MELANOCYTE; NONHUMAN; OPEN ANGLE GLAUCOMA; PIGMENT DISORDER; PRIORITY JOURNAL; REVIEW; SKIN DISCOLORATION; TRABECULECTOMY;

ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS; HUMANS; IRIS; IRIS DISEASES; PIGMENTATION DISORDERS; PROSTAGLANDINS F, SYNTHETIC;

EID: 12144257054     PISSN: 00215155     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10384-004-0110-y     Document Type: Review

References (85)

1. Alm A, Stjernschantz J, the Scandinavian Latanoprost Study Group. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Ophthalmology 1995;102:1743-1752.
2. Camras CB, the United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. A six-month, masked, multicenter trial in the United States. Ophthalmology 1996;103:138-147.
3. Watson P, Stjernschantz J, the Latanoprost Study Group. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology 1996;103:126-137.
4. Mishima HK, Masuda K, Kitazawa Y, Azuma I, Araie M. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study. Arch Ophthalmol 1996;114:929-932.
5. Parrish RK, Palmberg P, Sheu W-P, for the XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 2003;135: 688-703.
6. Gandolfi S, Simmons ST, Sturm R, Chen K, VanDenburgh A, for the Bimatoprost Study Group 3. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther 2001;18:110-121.
7. Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001;132:472-484.
8. 2-α analogues, latanoprost, and unoprostone isopropyl. J Glaucoma 2001;10: 487-492.
9. Tsukamoto H, Mishima HK, Kitazawa Y, et al. A comparative clinical study of latanoprost and isopropyl unoprostone in Japanese patients with primary open-angle glaucoma and ocular hypertension. J Glaucoma 2002;11:497-501.
10. Jampel HD, Bacharach J, Sheu WP, et al. Randomized clinical trial of latanoprost and unoprostone in patients with elevated intraocular pressure. Am J Ophthalmol 2002;134:863-871.
11. Susanna R Jr, Giampani J, Borges AS, et al. A double-masked, randomized clinical trial comparing latanoprost with unoprostone in patients with open-angle glaucoma or ocular hypertension. Ophthalmology 2001;108:259-263.
12. Ahn A, Schoenfelder J, McDermott J. A 5-year, multicenter, open-label, safety study of adjunctive latanoprost therapy for glaucoma. Arch Ophthalmol 2004;122:957-965.
13. Selen G, Stjernschantz J, Resul B. Prostaglandin-induced iridial pigmentation in primates. Surv Ophthalmol 1997;41:125-128.
14. Alm A, Widengard I. Latanoprost: experience of 2-year treatment in Scandinavia. Acta Ophthalmol Scand 2000;78:71-76.
15. Fellman RL, Sullivan EK, Ratliff M, et al. Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure. A 6-month, masked, multicenter trial. Ophthalmology 2002;109:998-1008.
16. Sherwood M, Brandt J, for the Bimatoprost Study Groups 1 and 2. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv Ophthalmol 2001;45:361-368.
17. Wistrand PJ, Stjernschantz J, Olsson K. The incidence and time-course of latanoprost induced iridial pigmentation as a function of eye color. Surv Ophthalmol 1997;41:S129-S138.
18. Chiba T, Kashiwagi K, Kogure S, et al. Iridial pigmentation induced by latanoprost ophthalmic solution in Japanese glaucoma patients. J Glaucoma 2001;10:406-410.
19. Chiba T, Kashiwagi K, Chiba N, et al. Comparison of iridial pigmentation between latanoprost and isopropyl unoprostone: a long-term prospective comparative study. Br J Ophthalmol 2003;87: 956-959.
20. Yamamoto T, Kitazawa Y. Iris-color change developed after topical isopropyl unoprostone treatment. J Glaucoma 1997;6:430-432.
21. Grierson I, Cracknell KPB, Pfeiffer N. The iris after prostanoid treatment. Curr Opin Ophthalmol 2001;12:112-118.
22. Wilkerson CR, Syed NS, Fisher MR, Robinson NL, Wallow IHL, Albert DM. Melanocytes and iris color: light microscopic findings. Arch Ophthalmol 1996;114:437-442.
23. Imesch PD, Bindly CD, Khademian Z, et al. Melanocytes and iris color. Electron microscopic findings. Arch Ophthalmol 1996;114: 443-447.
24. Prota G. Melanins and melanogenesis. San Diego: Academic Press, 1992.
25. Prota G, Hu DN, Vincensi MR, McCormick SA, Napolitano A. Characterization of melanins in human irides and cultured uveal melanocytes from eyes of different colors. Exp Eye Res 1998;67: 293-299.
26. Drago F, Marino A, La Manna C. α-Methyl-p-tyrosine inhibits latanoprost-induced melanogenesis in vitro. Exp Eye Res 1999;68: 85-90.
27. 2, and latanoprost on cultured human iridal melanocytes. Exp Eye Res 2000;70:113-120.
28. Dutkiewicz R, Albert DM, Levin LA. Effects of latanoprost on tyrosinase activity and mitotic index of cultured melanoma lines. Exp Eye Res 2000;70:563-569.
29. Imesch PD, Wallow IHL, Albert DM. The color of the human eye. A review of morphologic correlates and of some conditions that affect iridial pigmentation. Surv Ophthalmol 1997;41:S117-S123.
30. Wang N, Lindsey JD, Jones HL, Weinreb RN. Latanoprost does not induce mitosis in melanocytes within human iris organ cultures. Invest Ophthalmol Vis Sci 1999;40(Suppl):S675.
31. Loeffler KU, Sahm M, Spitznas M. Short-time application of latanoprost does not stimulate melanogenesis in bovine ocular melanin-containing cells in vitro. Ophthalmic Res 2001;33:102-106.
32. Grierson I, Pfeiffer N, Cracknell KPB, Appleton P. Histology and fine structure of the iris and outflow system following latanoprost therapy. Surv Ophthalmol 2002;217:176-184.
33. Pfeiffer N, Grierson I, Goldsmith H, Hochgesand D, Winkgen-Böhres A, Appleton P. Histological effects in the iris after 3 months of latanoprost therapy: the Mainz 1 study. Arch Ophthalmol 2001;119:191-196.
34. Stjernschantz J. Significance and time-course of prostaglandin-induced increase in iridial pigmentation in primates and man. In: Diestelhorst M, editor. Prostaglandins in ophthalmology. Heidelberg: Kaden Verlag. 1998:111-116.
35. 2α-isopropyl ester to latanoprost: a review of the development of Xalatan. The Proctor lecture. Invest Ophthalmol Vis Sci 2001;42:1134-1145.
36. Lindquist NG, Larsson BS, Stjernschantz J. Increased pigmentation of iridial melanocytes in primates induced by a prostaglandin analogue. Exp Eye Res 1999;68:431-436.
37. Lindquist NG, Larsson BS, Stjernschantz J, Sjöquist B. Age-related melanogenesis in the eye of mice, studied by microautoradiography of 3H-methimazole, a specific marker of melanin synthesis. Exp Eye Res 1998;67:259-264.
38. Prota G, Vincensi MR, Napolitano A, Selen G, Stjernschantz J. Latanoprost stimulates eumelanogenesis in iridial melanocytes of cynomolgus monkeys. Pigment Cell Res 2000; 13:147-150.
39. Camras CB, Way MB, Ritch R, et al. Latanoprost treatment for glaucoma: effects of treating for 1 year and of switching from timolol. Am J Ophthalmol 1998;126:390-399.
40. Watson PG, the Latanoprost Study Group. Latanoprost. Two years' experience of its use in the United Kingdom. Ophthalmology 1998;105:82-87.
41. Suzuki M, Mishima HK, Masuda K, Araie M, Kitazawa Y, Azuma I. Efficacy and safety of latanoprost eye drops for glaucoma treatment: a 1-year study in Japan. Jpn J Ophthalmol 2000;44:33-38.
42. Goldberg I, Cunha-Vaz J, Jakobsen J-E, et al. Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. J Glaucoma 2001;10:414-422.
43. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120: 701-713.
44. Hara T. Increased iris pigmentation after use of latanoprost in Japanese brown eyes. Nippon Ganka Gakkai Zasshi (J Jpn Ophthalmol Soc) 2001;105:314-321.
45. Garcia MA, Garcia PR. Efficacy of latanoprost monotherapy treatment in primary open-angle glaucoma. Arch Soc Esp Oftalmol 2002;77:269-274.
46. Teus MA, Arranz-Márquez E, Lucea-Suescun P. Incidence of iris colour change in latanoprost treated eyes. Br J Ophthalmol 2002;86:1085-1088.
47. Brion F, Bron A, Nordmann JP. Iris color change with latanoprost. What do the patients think? Invest Ophthalmol Vis Sci 1998;39(Suppl):S258.
48. Pfeiffer N, Grierson I, Goldsmith H, et al. Fine structural evaluation of the iris after unilateral treatment with latanoprost in patients undergoing bilateral trabeculectomy (the Mainz II study). Arch Ophthalmol 2003;121:23-31.
49. Cracknell KPB, Grierson I, Hogg P, Appleton P, Pfeiffer N. Latanoprost-induced iris darkening: A morphometric study of human peripheral iridectomies. Exp Eye Res 2003; 77:721-730.
50. Cracknell KP, Grierson I, Hogg P. Morphological effects of long-term exposure of iris tissue to latanoprost (Xalatan®). Invest Ophthalmol Vis Sci 2003;44:E-abstract 4399.
51. Grierson I, Lee WR, Albert DM. The fine structure of an iridectomy specimen from a patient with latanoprost-induced eye color change. Arch Ophthalmol 1999;117:394-396.
52. Freddo TF. Ultrastructure of the iris. Microsc Res Tech 1996;33: 369-389.
53. Eagle RC Jr. Iris pigmentation and pigmented lesions: an ultrastructural study. Trans Am Ophthalmol Soc 1988;86:581-687.
54. Tsai JC, Sivak-Callcott JA, Haik BG, et al. Latanoprost-induced iris heterochromia and open-angle glaucoma: a clinicopathologic report. J Glaucoma 2001;10:411-413.
55. Reynolds A, Murray PI, Colloby PS. Darkening of eyelashes in a patient treated with latanoprost. Eye 1998;12:741-743.
56. Demitsu T, Manabe M, Harima N, Sugiyama T, Yoneda K, Yamada N. Hypertrichosis induced by latanoprost. J Am Acad Dermatol 2001;44:721-723.
57. Uno H, Zimbric ML, Albert DM, Stjernschantz J. Effect of latanoprost on hair growth in the bald scalp of the stump-tailed macacque: a pilot study. Acta Derm Venereol 2002;82:7-12.
58. Voss NG, Lindstrom MJ, Zimbric ML, et al. Induction of anagen hair growth in telogen mouse skin by topical latanoprost application. Invest Ophthalmol Vis Sci 1999;40(Suppl):S676.
59. Stjernschantz J, Selen G, Astin M, Karlsson M, Resul B. Effect of latanoprost on regional blood flow and capillary permeability in the monkey eye. Arch Ophthalmol 1999;117:1363-1367.
60. Olsen EA, DeLong E. Transdermal viprostol in the treatment of male pattern baldness. J Am Acad Dermatol 1990;23:470-472.
61. Wand M. Latanoprost and hyperpigmentation of eyelashes. Arch Ophthalmol 1997;115:1206-1208.
62. Johnstone MA. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol 1997;124:544-547.
63. Strober BE, Potash S, Grossman ME. Eyelash hypertrichosis in a patient treated with topical latanoprost. Cutis 2001;67:109-110.
64. Johnstone MA. Brief latanoprost Rx induces hypertrichosis. Invest Ophthalmol Vis Sci 1998;39(Suppl):S258.
65. Mansberger SL, Cioffi GA. Eyelash formation secondary to latanoprost treatment in a patient with alopecia. Arch Ophthalmol 2000;118:718-719.
66. Wand M, Ritch R, Isbey EK Jr, Zimmerman TJ. Latanoprost and periocular skin color changes. Arch Ophthalmol 2001;119:614-615.
67. Kook MS, Lee K. Increased eyelid pigmentation associated with use of latanoprost. Am J Ophthalmol 2000;129:804-806.
68. Herndon LW, Williams RD, Wand M, Asrani S. Increased periocular pigmentation with ocular hypotensive lipid use in African Americans. Am J Ophthalmol 2003;135:713-715.
69. O'Toole L, Cahill M, O'Brien C. Eyelid hypertrichosis associated with latanoprost is reversible. Eur J Ophthalmol 2001;11:377-379.
70. Grierson I, Hogg P. The proliferative and migratory activities of trabecular meshwork cells. Prog Retin Eye Res 1995;15:3367.
71. Farrar SM, Shields MB. Current concepts in pigmentary glaucoma. Surv Ophthalmol 1993;37:233-252.
72. Lee WR. The pathology of the outflow system in primary and secondary glaucoma. Eye 1995;9:1-23.
73. Hu DN, McCormick SA, Ritch R. Studies of human uveal melanocytes in vitro: growth regulation of cultured human uveal melanocytes. Invest Ophthalmol Vis Sci 1993;34:2220-2227.
74. Hu DN, McCormick SA, Orlow SJ, Rosemblat S, Lin AY. Regulation of melanogenesis by human uveal melanocytes in vitro. Exp Eye Res 1997;64:397-404.
75. Lindsey JD, Jones HL, Hewitt EG, Angert M, Weinreb RN. Induction of tyrosinase gene transcription in human iris organ cultures exposed to latanoprost. Arch Ophthalmol 2001;119:853-860.
76. Stjernschantz J, Ocklind A, Wentzel P, Lake S, Hu D-N. Latanoprost-induced increase of tyrosinase transcription in iridial melanocytes. Acta Ophthalmol Scand 2000;78:618-622.
77. 2α receptor messenger RNA and protein in the cynomolgus monkey eye. Invest Ophthalmol Vis Sci 1996;37:716-726.
78. Kashiwagi K, Tsukamoto K, Suzuki M, Tsukahara S. Effects of isopropyl unoprostone and latanoprost on melanogenesis in mouse epidermal melanocytes. J Glaucoma 2002;11:57-64.
79. Zhan G-L, Toris CB, Meza JL, Camras CB. Unoprostone isopropyl ester darkens iris color in pigmented rabbits with sympathetic denervation. J Glaucoma 2003;12:383-389.
80. Bergh K, Wentzel P, Stjernschantz J. Production of prostaglandin e(2) by iridial melanocytes exposed to latanoprost acid, a prostaglandin F(2 alpha) analogue. J Ocul Pharmacol Ther 2002;18: 391-400.
81. 2 receptors. Proc Natl Acad Sci USA 1998;95: 15792-15797.
82. Zhan G-L, Toris CB, Camras CB, Wang Y-L, Bito LZ. Prostaglandin-induced iris color darkening. An experimental model. Arch Ophthalmol 1998;16:1065-1068.
83. Abdel-Malek ZA, Swope VB, Amornsiripanitch N, Nordlund JJ. In vitro modulation of proliferation and melanization of S91 melanoma cells by prostaglandins. Cancer Res 1987;47:3141-3146.
84. Woodward DR, Regan JW, Lake S, Ocklind A. The molecular biology and ocular distribution of prostanoid receptors. Surv Ophthalmol 1997;41:815-821.
85. Jimbow K. Formation, chemical compositions and functions of melanin pigments in mammals. In: Matoltsy AG, ed. Biology of the integument. New York: Springer Verlag. 1986:278.